Quest Diagnostics (NYSE: DGX) director acquires 72 shares in dividend reinvestment
Rhea-AI Filing Summary
Quest Diagnostics Inc. director Vicky B Gregg reported acquiring 72 shares of common stock on 2026-07-22 through a dividend reinvestment plan administered by the reporting person's broker. The shares were credited at $206.8080 per share, bringing the reported direct holdings to 18,386 shares. The disclosure notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but it was voluntarily reported earlier on Form 4.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 72 shares
Net Buy
1 txn
Insider
Gregg Vicky B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 72 | $206.808 | $15K |
Holdings After Transaction:
Common Stock — 18,386 shares (Direct)
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 72.0000 shares
Transaction price: $206.8080 per share
Shares held after transaction: 18386.0000 shares
3 metrics
Shares acquired
72.0000 shares
Common stock acquired on 2026-07-22 via dividend reinvestment plan
Transaction price
$206.8080 per share
Price per share for the 72 shares acquired through dividend reinvestment
Shares held after transaction
18386.0000 shares
Total directly owned Quest Diagnostics common shares following the acquisition
Key Terms
dividend reinvestment plan, Rule 16a-6, Form 5
3 terms
dividend reinvestment plan financial
"shares that were acquired pursuant to a dividend reinvestment plan administered"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
Form 5 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Vicky B Gregg report for Quest Diagnostics (DGX)?
Vicky B Gregg reported acquiring 72 shares of Quest Diagnostics common stock on 2026-07-22. The shares were obtained through a broker-administered dividend reinvestment plan and were voluntarily reported early on Form 4, although eligible for deferred Form 5 reporting under Rule 16a-6.
Was the Quest Diagnostics (DGX) Form 4 transaction made under a Rule 10b5-1 trading plan?
The Form 4’s Rule 10b5-1 checkbox was not selected, and the footnote instead describes a routine dividend reinvestment plan. The transaction reflects automatic reinvestment of dividends administered by the reporting person’s broker rather than a 10b5-1 trading plan.
Why was this Quest Diagnostics (DGX) dividend reinvestment reported on Form 4 instead of waiting for Form 5?
The dividend reinvestment was eligible for deferred reporting on Form 5 under Rule 16a-6. However, the reporting person chose to disclose the 72-share acquisition early on Form 4, as expressly stated in the footnote to the transaction.